Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05817890 · ClinicalTrials.gov registry record · Early Phase 1
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
A Early Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT05817890 is a Early Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT05817890, a Early Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This will be a Phase 1, open-label, single dose study of the Absorption, Metabolism, and Excretion of CYC065 in healthy male subjects.
Interventions
- DRUG Fadraciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2024-05-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05817890
The ClinicalTrials.gov registry entry for NCT05817890 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fadraciclib is the first listed.
NCT05817890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05817890 about?
NCT05817890 is a clinical study titled "Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects". This will be a Phase 1, open-label, single dose study of the Absorption, Metabolism, and Excretion of CYC065 in healthy male subjects.
What is the current status of trial NCT05817890?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2023-03-03. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05817890?
The interventions under investigation include: Fadraciclib (DRUG).
Who is sponsoring clinical trial NCT05817890?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.